Table 1

Sample characteristics
Item Controls Post-diagnosis p
n (%) n (%)
Age* (years) 52.58 ± 7.19 57.29 ± 11.82 0.102
  ≤ 55 17 (70.8) 13 (54.2)
  > 55 7 (29.2) 11 (45.8)
Educational attainment
  Primary education 18 (75) 17 (73.9) 0.839
  Secondary education 4 (16.7) 3 (13.0)
  Higher education 2 (8.3) 3 (13.0)
Partner age* (years) 52.54 ±11.88 55.96 ±13.62 0.359
  ≤ 55 14 (58.3) 13 (54.2)
  > 55 10 (41.7) 10 (41.7)
Partner education
  Primary education 15 (65.2) 15 (65.2) 1.000
  Secondary education 6 (26.1) 6 (26.1)
  Higher education 2 (8.7) 2 (8.7)
No. partners
  One partner 17 (70.8) 13 (54.2) 0.371
  More than one partner 7 (29.2) 11 (45.8)
Family history
  Negative - 20 (83.3)
  Positive - 4 (16.7)
HRT
  No prior therapy - 20 (83.3)
  Prior therapy - 4 (16.7)
Clinical stage
  IIA–B - 8 (33.3)
  IIIA–B - 16 (66.7)
Tumor size
  T2 - 8 (33.3)
  T3 - 6 (25.0)
  T4 - 10 (41.7)
Receptor / HER2/neu status
  ER+/PR+/HER2+ - 1 (1.4)
  ER+/PR–/ HER2+ - 0 (0)
  ER+/PR+/HER2– - 9 (12.5)
  ER+/PR–/HER2– - 4 (5.6)
  ER–/PR+/HER2+ - 0 (0)
  ER–/PR–/HER2+ - 2 (2.8)
  ER–/PR+/HER2– - 0 (0)
  ER–/PR–/HER2– - 8 (11.1)
Histologic grade
  Grade I - 1 (4.2)
  Grade II - 17 (70.8)
  Grade III - 6 (25.0)

T2 = 2–5 cm; T3 = >5 cm; T4 = inflammatory tumor or invasion of chest wall or skin.

ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2; HRT, hormone replacement therapy; PR, progesterone receptor.

*Mean ± SD.

t-Student Test.

Pearson’s Chi-Square.

Cavalheiro et al.

Cavalheiro et al. BMC Women's Health 2012 12:28   doi:10.1186/1472-6874-12-28

Open Data